Therapies in Refractory Metastatic Renal Cell Carcinoma
As the therapeutic landscape for metastatic clear cell renal cell carcinoma (mccRCC) expands to include vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and immunotherapies, new challenges are in place for evaluating and treating refractory disease. Assessing and m...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Société Internationale d’Urologie Journal |
| Subjects: | |
| Online Access: | https://siuj.org/index.php/siuj/article/download/223/163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850241118943313920 |
|---|---|
| author | Stephanie Berg Martin Angel Kathryn E. Beckermann Frede Donskov Chung-Han Lee Pavlos Msaouel Rana R. McKay Tian Zhang |
| author_facet | Stephanie Berg Martin Angel Kathryn E. Beckermann Frede Donskov Chung-Han Lee Pavlos Msaouel Rana R. McKay Tian Zhang |
| author_sort | Stephanie Berg |
| collection | DOAJ |
| description | As the therapeutic landscape for metastatic clear cell renal cell carcinoma (mccRCC) expands to include vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and immunotherapies, new challenges are in place for evaluating and treating refractory disease. Assessing and managing refractory disease has several elements: (1) the mechanism(s) of front-line treatment, (2) timing of progressive disease, (3) rapidity and sites of progressing disease, (4) use of adjuvant therapy, and (5) incorporation of surgical and radiation techniques. These variables all have distinct impact on the biology of refractory or resistant mccRCC. A better understanding of the essential mechanisms of both primary and secondary immunotherapy resistance will inform biomarker development and therapeutic strategies in the refractory setting. This paper addresses the current understanding of treatment sequencing in refractory mccRCC, focusing on treatment options with prospective clinical trial data, considers refractory mccRCC after adjuvant immunotherapy, and incorporates radiation or surgical resection for oligoprogressive disease. |
| format | Article |
| id | doaj-art-a5cbce987c764e8f97ba273c98c2ab8f |
| institution | OA Journals |
| issn | 2563-6499 |
| language | English |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Société Internationale d’Urologie Journal |
| spelling | doaj-art-a5cbce987c764e8f97ba273c98c2ab8f2025-08-20T02:00:41ZengMDPI AGSociété Internationale d’Urologie Journal2563-64992022-11-013647848410.48083/KGTQ6832Therapies in Refractory Metastatic Renal Cell CarcinomaStephanie BergMartin AngelKathryn E. BeckermannFrede DonskovChung-Han LeePavlos MsaouelRana R. McKayTian ZhangAs the therapeutic landscape for metastatic clear cell renal cell carcinoma (mccRCC) expands to include vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and immunotherapies, new challenges are in place for evaluating and treating refractory disease. Assessing and managing refractory disease has several elements: (1) the mechanism(s) of front-line treatment, (2) timing of progressive disease, (3) rapidity and sites of progressing disease, (4) use of adjuvant therapy, and (5) incorporation of surgical and radiation techniques. These variables all have distinct impact on the biology of refractory or resistant mccRCC. A better understanding of the essential mechanisms of both primary and secondary immunotherapy resistance will inform biomarker development and therapeutic strategies in the refractory setting. This paper addresses the current understanding of treatment sequencing in refractory mccRCC, focusing on treatment options with prospective clinical trial data, considers refractory mccRCC after adjuvant immunotherapy, and incorporates radiation or surgical resection for oligoprogressive disease.https://siuj.org/index.php/siuj/article/download/223/163refractory metastatic clear cell renal cell carcinomavascular endothelial growth factor receptor tyrosine kinase inhibitorimmunotherapy resistance |
| spellingShingle | Stephanie Berg Martin Angel Kathryn E. Beckermann Frede Donskov Chung-Han Lee Pavlos Msaouel Rana R. McKay Tian Zhang Therapies in Refractory Metastatic Renal Cell Carcinoma Société Internationale d’Urologie Journal refractory metastatic clear cell renal cell carcinoma vascular endothelial growth factor receptor tyrosine kinase inhibitor immunotherapy resistance |
| title | Therapies in Refractory Metastatic Renal Cell Carcinoma |
| title_full | Therapies in Refractory Metastatic Renal Cell Carcinoma |
| title_fullStr | Therapies in Refractory Metastatic Renal Cell Carcinoma |
| title_full_unstemmed | Therapies in Refractory Metastatic Renal Cell Carcinoma |
| title_short | Therapies in Refractory Metastatic Renal Cell Carcinoma |
| title_sort | therapies in refractory metastatic renal cell carcinoma |
| topic | refractory metastatic clear cell renal cell carcinoma vascular endothelial growth factor receptor tyrosine kinase inhibitor immunotherapy resistance |
| url | https://siuj.org/index.php/siuj/article/download/223/163 |
| work_keys_str_mv | AT stephanieberg therapiesinrefractorymetastaticrenalcellcarcinoma AT martinangel therapiesinrefractorymetastaticrenalcellcarcinoma AT kathrynebeckermann therapiesinrefractorymetastaticrenalcellcarcinoma AT frededonskov therapiesinrefractorymetastaticrenalcellcarcinoma AT chunghanlee therapiesinrefractorymetastaticrenalcellcarcinoma AT pavlosmsaouel therapiesinrefractorymetastaticrenalcellcarcinoma AT ranarmckay therapiesinrefractorymetastaticrenalcellcarcinoma AT tianzhang therapiesinrefractorymetastaticrenalcellcarcinoma |